Article
Gastroenterology & Hepatology
Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, Floriane Fusil, Fouzia Amirache, Axel Rossi, Anne-Flore Legrand, Emilie Charles, Serena Vegna, Rayan Farhat, Michel Rivoire, Guillaume Passot, Nicolas Gadot, Barbara Testoni, Charlotte Bach, Thomas F. Baumert, Anastasia Hyrina, Rudolf K. Beran, Fabien Zoulim, Andre Boonstra, Hildegard Buening, Eloi R. Verrier, Francois-Loic Cosset, Simon P. Fletcher, Anna Salvetti, David Durantel
Summary: This study elucidates the molecular mechanisms underlying how HDV interferes with HBV in patients with chronic coinfection. The researchers found that HDV induces the expression of interferon-stimulated genes (ISGs), and these genes are upregulated in HDV/HBV-coinfected patients. Inhibiting the hepatocyte's response to interferon partially restores the levels of HBV.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ohad Etzion, Saeed Hamid, Yoav Lurie, Edward J. Gane, David Yardeni, Sarah Duehren, Nimrah Bader, Anat Nevo-Shor, Saleh Muhammad Channa, Scott J. Cotler, Minaz Mawani, Om Parkash, Harel Dahari, Ingrid Choong, Jeffrey S. Glenn
Summary: This study investigates a new treatment for chronic HDV infection using Lambda monotherapy, which shows virologic response during and following treatment.
Review
Gastroenterology & Hepatology
Lisa Sandmann, Heiner Wedemeyer
Summary: Interferon-alfa has been the main treatment for hepatitis D virus (HDV) infection, but only a portion of patients benefit from it. Successful interferon treatment is associated with improved long-term clinical outcomes. Although alternative treatments are being developed, pegylated interferon-alfa still plays an important role. There is a need for better biomarkers to select patients who are likely to benefit from interferon-based treatments.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Adriana Palom, Sara Sopena, Mar Riveiro-Barciela, Angela Carvalho-Gomes, Antonio Madejon, Sergio Rodriguez-Tajes, Luisa Roade, Maria Garcia-Eliz, Javier Garcia-Samaniego, Sabela Lens, Marina Berenguer-Hayme, Francisco Rodriguez-Frias, Helena Hernandez-Evole, Ana Isabel Gil-Garcia, Ana Barreira, Rafael Esteban, Maria Buti
Summary: This study evaluated changes in serum HDV-RNA concentrations in 56 untreated chronic hepatitis delta (CHD) patients. Results showed that 25% of patients had a >= 2 log(10) decline in HDV-RNA levels, while 20% achieved undetectable HDV-RNA over a mean follow-up of 5.6 years. The decline was associated with ALT decrease.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulzezur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: In this study, it was found that bulevirtide is effective in inhibiting the entry of hepatitis D virus and reducing the progression of liver disease in patients with chronic hepatitis B. The recommended dosage of bulevirtide is 2 mg or 10 mg per day.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulze zur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: Bulevirtide treatment reduces HDV RNA and ALT levels in patients with chronic hepatitis D, with a dose-dependent effect.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Aigerim Abdrakhman, Aiymkul Ashimkhanova, Wassim Y. Almawi
Summary: The study shows that peginterferon has limited effectiveness in the treatment of chronic HDV, with only one-third of patients achieving viral clearance and normalization of ALT levels. Furthermore, HBsAg clearance with seroconversion to anti-HBs is rarely observed among chronic HDV patients.
ANTIVIRAL RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Julian Hercun, Grace E. Kim, Ben L. Da, Yaron Rotman, David E. Kleiner, Richard Chang, Jeffrey S. Glenn, Jay H. Hoofnagle, Christopher Koh, Theo Heller
Summary: Extended course of peginterferon therapy resulted in sustained clearance of HDV RNA and favorable clinical outcomes in more than half of patients, with about a third clearing HBsAg. Responders had significantly lower rates of death or liver-related events compared to non-responders.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Virology
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen
Summary: Ropeginterferon alfa-2b is a promising treatment option for MPN and chronic viral hepatitis due to its favorable pharmacokinetic profile and demonstrated efficacy in clinical studies. Administered once every two weeks, it has shown to be well-tolerated and effective in treating chronic hepatitis B, C, and D.
Article
Virology
Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang
Summary: This study found that single-nucleotide polymorphism CXCL13_rs76084459 is significantly associated with response to PegIFNa therapy in patients with chronic hepatitis B. Furthermore, a polygenic score composed of 6 SNPs including CXCL13_rs76084459 has a better predictive value for PegIFNa treatment response.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Medicine, General & Internal
Tarik Asselah, Mario Rizzetto
Summary: Hepatitis D virus (HDV), also known as hepatitis delta virus, is a defective, hepatotropic pathogenic agent. It requires the hepatitis B surface antigen (HBsAg) provided by hepatitis B virus (HBV) for its life cycle. HDV is mainly transmitted through contaminated syringes used by intravenous drug users. It is characterized by unique biological characteristics and severe medical effects. The global prevalence of HDV infection remains uncertain, and effective therapies are urgently needed.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Microbiology
Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau
Summary: HBV infection is a global public health issue and a major cause of cirrhosis and HCC; current therapies for chronic hepatitis B and D are suboptimal and new therapeutic agents targeting different stages of viral replicative cycle are necessary; promising compounds such as entry inhibitors, cccDNA inhibitors, siRNAs, capsid assembly modulators and nucleic acid polymers are in various stages of clinical development.
Article
Medicine, General & Internal
Julian Hercun, Theo Heller, Jeffrey S. Glenn, David E. Kleiner, Christopher Koh
Summary: This study evaluates the impact of nucleos(t)ide analogs on the histological appearance of chronic HDV infection and finds that patients on nucleos(t)ide analogs demonstrate a unique membranous staining pattern.
FRONTIERS IN MEDICINE
(2023)
Review
Biotechnology & Applied Microbiology
Helen Y. Xu, Jamie O. Yang, Phillip H. Chen, Steven-Huy B. Han
Summary: Bulevirtide represents a major shift in treatment for chronic HDV, for which there is significant unmet need. Trials that compared bulevirtide in combination with interferon alpha vs interferon alpha monotherapy demonstrated significant increase in virologic response. Overall, treatment with different doses of bulevirtide were comparable. Bulevirtide was generally well tolerated, and no serious adverse events occurred. Understanding the true prevalence of HDV, as well as continued studies of emerging drugs will prove valuable to the larger goal of eradication of Hepatitis D.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Review
Immunology
Mamun Al-Mahtab, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Julio Cesar Aguilar, Gerardo Guillen, Yoichi Hiasa
Summary: An open-level clinical trial has shown that a therapeutic vaccine, NASVAC, containing HBsAg and HBcAg, is effective and safer than Peg-IFN in treating CHB patients. The study also suggests that NASVAC may be particularly beneficial for patients with HBV genotype-D.
